Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020198531 - CHIMERIC ANTIGEN RECEPTOR MODIFIED T-CELLS (CAR-T) FOR THE TREATMENT OF HEMATOLOGICAL AND SOLID TUMOR CANCERS

Publication Number WO/2020/198531
Publication Date 01.10.2020
International Application No. PCT/US2020/025069
International Filing Date 26.03.2020
IPC
C07K 14/05 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
01DNA viruses
03Herpetoviridae, e.g. pseudorabies virus
05Epstein-Barr virus
C07K 16/28 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Applicants
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US]/[US]
Inventors
  • PRUSSAK, Charles, E.
  • KIPPS, Thomas, J.
  • WIDHOPF, George, F.
  • OH, Christopher, S.
Agents
  • HETZER-EGGER, Claudia
  • ADAMS, Lisa
  • BAUER, John, A.
  • AMENDT, Kevin, C.
  • AZRIN, Linda, B.
Priority Data
62/824,08026.03.2019US
62/931,10305.11.2019US
62/969,56903.02.2020US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CHIMERIC ANTIGEN RECEPTOR MODIFIED T-CELLS (CAR-T) FOR THE TREATMENT OF HEMATOLOGICAL AND SOLID TUMOR CANCERS
(FR) LYMPHOCYTES T MODIFIÉS PAR UN RÉCEPTEUR ANTIGÉNIQUE CHIMÉRIQUE (CAR-T) POUR LE TRAITEMENT DE CANCERS HÉMATOLOGIQUES ET TUMORAUX SOLIDES
Abstract
(EN)
Provided herein is a chimeric antigen receptor (CAR) and CAR-expressing immune cells that target human RORI expressed aberrantly on a tumor cancers. Described herein are chimeric antigen receptors that target human ROR-1, cell compositions expressing the chimeric antigen receptors, and methods and uses of the chimeric antigen receptors and/or the cell compositions. The chimeric antigen receptors described herein can be expressed by the T lymphocytes isolated from an individual afflicted with cancer and re-administered to the individual.
(FR)
La présente invention concerne un récepteur antigénique chimère (CAR) et des cellules immunitaires exprimant un CAR qui ciblent le ROR1 humain exprimé de manière aberrante sur des cancers tumoraux.
Latest bibliographic data on file with the International Bureau